Table 3 Glucose tolerance categories for cases and controls at baseline and after 1 year of follow-up

From: Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion

  Baseline Follow-up
Cases NGT: 7 (53.8%) NGT: 7 (53.8%)
IGT: 4 (30.8%) IGT: 4 (30.8%)
CFRD: 2 (15.4%) CFRD: 2 (15.4%)
Controls NGT: 4 (30.8%) NGT: 5 (38.5%)
IGT: 7 (53.8%) IGT: 5 (38.5%)
CFRD: 2 (15.4%) CFRD: 3 (23.1%)
  1. Data are presented as count (fraction)